280 Life Science patents (classification A61K) were issued by the US Patent and Trademark Office on Tuesday 4 October 2016 (click here). Three went to Australian assignees.
US Patent 9,458,093 went to Vectus Biosystems (ASX: VBS) for Compositions for the treatment of hypertension and/or fibrosis. This patent covers the use of vasoactive intestinal peptide (VIP) fragment in these two conditions.
US Patent 9,457,107 went to the University of Melbourne for Cage amine ligands for metallo-radiopharmaceuticals. This patent covers metal-binding organic compounds that could be useful in radiotherapy.
US Patent 9,457,062 went to Invion (ASX: IVX) for Chaperonin 10-induced immunomodulation. This patent covers chaperonin 10 polypeptides, useful for activating Toll-Like Receptors.
Over the last twelve months the Australian Life Science sector has been granted 123 US patents, versus 129 in the previous corresponding period.
To look at US Life Science patent issuance since the beginning of 2014 to Australian assignees, click here. For US Life Science patent issuance to New Zealand assignees click here.